MERIT-HF
1999
Metoprolol CR/XL Randomized Intervention Trial in Heart Failure
In 3,991 patients with HFrEF (EF ≤ 0.40, NYHA II–IV), metoprolol CR/XL reduced all-cause mortality compared with placebo.
Result
Primary endpoint: All-cause mortality
7.2 % vs 11.0 % per patient-year (34 % RRR).
- Subtopic
- Beta-blockade
- Design
- Double-blind RCT, terminated early
- Relevance
- Practice-defining: a trial the guidelines cite as evidence.
- Source
- MERIT-HF Study Group. Lancet. 1999;353(9169):2001-2007.doi 10.1016/S0140-6736(99)04440-2
Discussion & critique
Established β-blockade as a pillar. Together with CIBIS-II (bisoprolol) and COPERNICUS (carvedilol), defined the prognostic β-blockers in HF.